On July 26, the Japanese company Daiichi Sankyo Co. Ltd.” announced that the US Food and Drug Administration (FDA) has approved its combination drug Tribenzor™ (olmesartan + amlodipine + hydrochlorothiazide) for the treatment of hypertension in patients whose blood pressure is unresponsive to other combination antihypertensive drugs. means. Daiichi Sankyo notes that Tribenzor simplifies dosing regimens and also reduces the cost of treating patients who have to take three drugs – olmesartan, amlodipine and hydrochlorothiazide – to keep blood pressure levels within recommended limits.
In a study of 2492 patients with hypertension, Tribenzor once daily resulted in greater reductions in systolic and diastolic blood pressure after 8 weeks of therapy compared with dual combination therapy of angiotensin II receptor antagonists with calcium channel blockers or diuretics.
Based on materials: apteka.ua